Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained before any assessment is performed. Patients with mild-to-moderate systolic hypertension, untreated or currently taking antihypertensive therapy.
Ability to communicate and comply with all study requirements and demonstrate good medication compliance (≥ 80% compliance rate) during the run-in period.
You may not be if
Severe hypertension
History of angioedema, drug-related or otherwise, as reported by the patient.
Pregnant or nursing (lactating) women.
Women of child-bearing potential (WOCBP), UNLESS they are using adequate birth control methods.
History or evidence of a secondary form of hypertension.
Clareo Health | An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
